Download
00432_2024_Article_5884.pdf 1,00MB
WeightNameValue
1000 Titel
  • Rare tumours of the pancreas: monocentric study
1000 Autor/in
  1. Bauschke, Astrid |
  2. Altendorf-Hofmann, Annelore |
  3. Ali-Deeb, Aladdin |
  4. Ardelt, Michael |
  5. Dondorf, Felix |
  6. Rauchfuss, Falk |
  7. Rohland, Oliver |
  8. Tekbaș, Aysun |
  9. Settmacher, Utz |
1000 Verlag Springer Berlin Heidelberg
1000 Erscheinungsjahr 2024
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2024-07-13
1000 Erschienen in
1000 Quellenangabe
  • 150(7):349
1000 Copyrightjahr
  • 2024
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00432-024-05884-2 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11246325/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • <jats:title>Abstract</jats:title><jats:sec> <jats:title>Purpose</jats:title> <jats:p>The biology of rare pancreatic tumours, which differs from that of ductal pancreatic cancer, requires increased attention. Although the majority of rare pancreatic tumours are benign, it is difficult to decide whether an invasive component exists without complete removal of the lesion, despite considerable progress in diagnosis. We are investigating a large cohort of patients with histologically confirmed epithelial non-ductal non-neuroendocrine neoplasms of the pancreas.</jats:p> </jats:sec><jats:sec> <jats:title>Methods</jats:title> <jats:p>Here we analyze long-term survival from patients, who underwent resection of histologically confirmed epithelial non-ductal non-neuroendocrine neoplasms of the pancreas. At our department between Jan 1st, 1999, and Dec 31st, 2019. The median follow-up was 61 (range 0–168) month. All statistical analyses were performed using SPSS 26.0 (IBM, Chicago, IL, USA) software.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>46 patients (48%) were followed up for more than 5 years, 18 patients (19%) for more than 10 years. The 5-year and 10-year survival rates for rare non-invasive pancreatic tumours were 72% and 55% respectively. The proportion of rare tumour entities (non-ductal and non-neuroendocrine) increased continuously and statistically significantly (p = 0.004) from 4.2 to 12.3% in our clinic between 1999 and 2019. If there is no invasive growth yet, there is a varying risk of malignant degeneration in the course of the disease. Therefore, the indication for pancreatic resection is still the subject of discussion.</jats:p> </jats:sec><jats:sec> <jats:title>Conclusion</jats:title> <jats:p>The long-term prognosis of rare epithelial pancreatic tumours after R0 resection—even if they are already malignant—is much better than that of ductal pancreatic cancer.</jats:p> </jats:sec>
1000 Sacherschließung
lokal Female [MeSH]
lokal Follow-Up Studies [MeSH]
lokal Aged, 80 and over [MeSH]
lokal Aged [MeSH]
lokal Pancreatic Neoplasms/pathology [MeSH]
lokal Adult [MeSH]
lokal Humans [MeSH]
lokal Retrospective Studies [MeSH]
lokal Middle Aged [MeSH]
lokal Survival Rate [MeSH]
lokal Long-term survival
lokal Male [MeSH]
lokal Pancreatectomy [MeSH]
lokal Rare epithelial pancreatic tumours
lokal Research
lokal Prognosis [MeSH]
lokal Young Adult [MeSH]
lokal Pancreatic Neoplasms/mortality [MeSH]
lokal Surgery
lokal Pancreatic Neoplasms/surgery [MeSH]
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0002-9941-5323|https://frl.publisso.de/adhoc/uri/QWx0ZW5kb3JmLUhvZm1hbm4sIEFubmVsb3Jl|https://frl.publisso.de/adhoc/uri/QWxpLURlZWIsIEFsYWRkaW4=|https://frl.publisso.de/adhoc/uri/QXJkZWx0LCBNaWNoYWVs|https://frl.publisso.de/adhoc/uri/RG9uZG9yZiwgRmVsaXg=|https://frl.publisso.de/adhoc/uri/UmF1Y2hmdXNzLCBGYWxr|https://frl.publisso.de/adhoc/uri/Um9obGFuZCwgT2xpdmVy|https://frl.publisso.de/adhoc/uri/VGVrYmHImSwgQXlzdW4=|https://frl.publisso.de/adhoc/uri/U2V0dG1hY2hlciwgVXR6
1000 Hinweis
  • DeepGreen-ID: 0e6c810321c04356a6ce312efce6983a ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Förderer
  1. Universitätsklinikum Jena |
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
  1. Rare tumours of the pancreas: monocentric study
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Universitätsklinikum Jena |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6518360.rdf
1000 Erstellt am 2025-07-05T10:37:06.748+0200
1000 Erstellt von 322
1000 beschreibt frl:6518360
1000 Zuletzt bearbeitet 2025-08-19T19:41:13.488+0200
1000 Objekt bearb. Tue Aug 19 19:41:13 CEST 2025
1000 Vgl. frl:6518360
1000 Oai Id
  1. oai:frl.publisso.de:frl:6518360 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source